The NeurologyLive® multiple sclerosis (MS) clinical focus page offers information, podcasts, videos, and news about the latest study and clinical trial findings, FDA actions, clinical guideline updates, and expert interviews related to the care and management of patients with MS, including relapsing MS and progressive MS, as well as related disorders such as neuromyelitis optica spectrum disorder.
Check out some of NeurologyLive®'s featured content in the carousel below.
Anti-CD20 Therapy Ublituximab Gains FDA Approval for Relapsing Multiple SclerosisDecember 28th 2022
Marketed as Briumvi, the TG Therapeutics treatment becomes the third anti-CD20 agent approved for relapsing multiple sclerosis and is expected to become available in the first quarter of 2023.
Key Points for the Management of Multiple SclerosisDecember 27th 2022
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, provide key takeaways for the treatment of patients with multiple sclerosis.
Digital Interventions and Wearable Devices for Preventative Care in MS: Michelle Chen, PhDDecember 22nd 2022
The neuropsychologist at Rutgers University, in New Brunswick, New Jersey, spoke about the different types of nonpharmacological digital interventions for multiple sclerosis. [WATCH TIME: 4 minutes]
Treatment Interruption and Cessation for Multiple SclerosisDecember 20th 2022
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, review data on short-term interruption of ponesimod vs teriflunomide when treating multiple sclerosis.
Linking the Latest Research to Clinical Care in MS: Robert Bermel, MDDecember 19th 2022
The director of the Mellen Center for MS at Cleveland Clinic offered an overview of the State of the Science Summit that was held on November 10, 2022, featuring a panel of expert clinicians. [WATCH TIME: 4 minutes]
Patient-Reported Outcomes Improved Through Earlier Initiation of MS TreatmentDecember 19th 2022
Using a cohort of more than 2500 patients with MS on disease-modifying therapies, treatment initiation within the first 2 years of disease onset was more beneficial on patient-reported outcomes than 2-4 years postonset.
Future Implications of New Framework to Characterize Multiple Sclerosis: Ruth Ann Marrie, MD, PhD, FRCPCDecember 14th 2022
The professor of medicine at the University of Manitoba detailed the implications of a new paper suggesting changes to the characterization of MS phenotypes and how it might impact previously approved therapies. [WATCH TIME: 3 minutes]
Switching Therapies for Patients with Multiple SclerosisDecember 13th 2022
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, discuss their approach to switching treatments for patients with multiple sclerosis and the timing between therapies.
Sequencing Disease-Modifying Therapies in Multiple SclerosisDecember 13th 2022
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, share their thoughts on sequencing disease-modifying therapies when treating patients with multiple sclerosis.